Mark James Litton Sells 5,156 Shares of Athira Pharma (NASDAQ:LONA) Stock

Athira Pharma, Inc. (NASDAQ:LONA) CEO Mark James Litton sold 5,156 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $5.37, for a total transaction of $27,687.72. Following the transaction, the chief executive officer owned 57,926 shares of the company’s stock, valued at $311,062.62. This represents a 8.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Athira Pharma Trading Down 1.3%

LONA opened at $5.30 on Friday. Athira Pharma, Inc. has a 52-week low of $2.20 and a 52-week high of $8.36. The firm has a market cap of $20.88 million, a price-to-earnings ratio of -0.55 and a beta of 2.68.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on LONA shares. Wall Street Zen lowered shares of Athira Pharma from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Mizuho raised Athira Pharma from a “neutral” rating to an “outperform” rating and set a $10.00 target price for the company in a report on Thursday, February 19th. Zacks Research upgraded Athira Pharma to a “hold” rating in a research report on Friday, February 27th. Weiss Ratings initiated coverage on Athira Pharma in a research note on Wednesday, February 11th. They issued a “sell (d-)” rating on the stock. Finally, Cantor Fitzgerald started coverage on Athira Pharma in a research report on Thursday, February 26th. They set an “overweight” rating for the company. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $10.00.

About Athira Pharma

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.